×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
STRO – sutro biopharma, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
STRO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/1
08:52 am
stro
Sutro Biopharma Announces 1-for-10 Reverse Stock Split [Yahoo! Finance]
Medium
Report
Sutro Biopharma Announces 1-for-10 Reverse Stock Split [Yahoo! Finance]
12/1
08:00 am
stro
Sutro Biopharma Announces 1-for-10 Reverse Stock Split
High
Report
Sutro Biopharma Announces 1-for-10 Reverse Stock Split
11/26
02:19 pm
stro
Sutro Biopharma (NASDAQ:STRO) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Sutro Biopharma (NASDAQ:STRO) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
11/12
11:04 am
stro
Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day [Yahoo! Finance]
Low
Report
Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day [Yahoo! Finance]
11/12
10:00 am
stro
Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day
Low
Report
Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day
11/7
11:30 pm
stro
Sutro Biopharma (NASDAQ:STRO) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $2.00 price target on the stock.
Low
Report
Sutro Biopharma (NASDAQ:STRO) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $2.00 price target on the stock.
11/6
06:34 pm
stro
Sutro Biopharma GAAP EPS of -$0.67 misses by $0.27, revenue of $9.69M beats by $0.56M [Seeking Alpha]
Medium
Report
Sutro Biopharma GAAP EPS of -$0.67 misses by $0.27, revenue of $9.69M beats by $0.56M [Seeking Alpha]
11/6
04:30 pm
stro
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
High
Report
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
12/3
04:30 pm
stro
Form 8-K SUTRO BIOPHARMA, INC. For: Dec 01
Medium
Report
Form 8-K SUTRO BIOPHARMA, INC. For: Dec 01
11/6
05:01 pm
stro
Form 10-Q SUTRO BIOPHARMA, INC. For: Sep 30
Medium
Report
Form 10-Q SUTRO BIOPHARMA, INC. For: Sep 30
11/6
04:45 pm
stro
Form 8-K SUTRO BIOPHARMA, INC. For: Nov 06
Medium
Report
Form 8-K SUTRO BIOPHARMA, INC. For: Nov 06
10/23
04:07 pm
stro
Form SCHEDULE 13G SUTRO BIOPHARMA, INC. Filed by: Affinity Asset Advisors, LLC
Low
Report
Form SCHEDULE 13G SUTRO BIOPHARMA, INC. Filed by: Affinity Asset Advisors, LLC
10/16
08:20 am
stro
Form 4 SUTRO BIOPHARMA, INC. For: Oct 15 Filed by: Gerber Hans-Peter
Medium
Report
Form 4 SUTRO BIOPHARMA, INC. For: Oct 15 Filed by: Gerber Hans-Peter
10/16
08:19 am
stro
Form 4 SUTRO BIOPHARMA, INC. For: Oct 15 Filed by: Chow Gregory K.
Medium
Report
Form 4 SUTRO BIOPHARMA, INC. For: Oct 15 Filed by: Chow Gregory K.
10/16
08:17 am
stro
Form 4 SUTRO BIOPHARMA, INC. For: Oct 15 Filed by: Chung Jane
Medium
Report
Form 4 SUTRO BIOPHARMA, INC. For: Oct 15 Filed by: Chung Jane
10/16
08:16 am
stro
Form 4 SUTRO BIOPHARMA, INC. For: Oct 15 Filed by: MATSUI CONNIE
Medium
Report
Form 4 SUTRO BIOPHARMA, INC. For: Oct 15 Filed by: MATSUI CONNIE
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/24
Sutro Biopharma Inc (NASDAQ: STRO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating.
17.6%
3/16 Form S-8 SUTRO BIOPHARMA, INC. 17.4%
3/19 Sutro Biopharma Inc (NASDAQ: STRO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock. 16.8%
1/31 Form 4 SUTRO BIOPHARMA, INC. For: Jan 29 Filed by: ALBINI EDWARD C 15.5%
10/21 Sutro Biopharma Inc (NASDAQ: STRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock. 9.8%
9/5 Sutro Biopharma Inc (NASDAQ: STRO) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $16.00 price target on the stock. 7.7%
4/20 Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate 7.4%
6/18 Sutro Biopharma to Present at the JMP Securities Life Sciences Conference 6.9%
3/4 Sutro Biopharma to Present Innovative Cancer Therapy Approach Using Precise Tumor Targeted Immunostimulants at World ADC London 6.2%
10/4 Form S-3 SUTRO BIOPHARMA, INC. 5.9%
3/16 Form S-8 SUTRO BIOPHARMA, INC. 17.4%
3/19 Sutro Biopharma Inc (NASDAQ: STRO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock. 16.8%
1/31 Form 4 SUTRO BIOPHARMA, INC. For: Jan 29 Filed by: ALBINI EDWARD C 15.5%
10/21 Sutro Biopharma Inc (NASDAQ: STRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock. 9.8%
9/5 Sutro Biopharma Inc (NASDAQ: STRO) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $16.00 price target on the stock. 7.7%
4/20 Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate 7.4%
6/18 Sutro Biopharma to Present at the JMP Securities Life Sciences Conference 6.9%
3/4 Sutro Biopharma to Present Innovative Cancer Therapy Approach Using Precise Tumor Targeted Immunostimulants at World ADC London 6.2%
10/4 Form S-3 SUTRO BIOPHARMA, INC. 5.9%
TOP News Decliners
3/16
Sutro Biopharma Inc (NASDAQ: STRO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating.
-39.3%
4/24 Form DEF 14A SUTRO BIOPHARMA, INC. For: Jun 05 -16.5%
10/7 Sutro Bio up 22% after mixed shelf filing [Seeking Alpha] -12.6%
3/10 Sutro Biopharma Inc (NASDAQ: STRO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -10.4%
2/27 Sutro Biopharma to Present at the Cowen and Company 40th Annual Health Care Conference -8.3%
5/14 Q1/2019 3/31/2019 EPS -0.620 ZacksConsensus N/A ActVsEst N/A - N/A -7.7%
8/14 Q2/2019 6/30/2019 EPS -0.600 ZacksConsensus N/A ActVsEst N/A - N/A -7.0%
9/30 Form 4 SUTRO BIOPHARMA, INC. For: Sep 26 Filed by: ALBINI EDWARD C -4.4%
3/12 Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck -3.9%
1/8 Sutro Biopharma Appoints James Panek to Board of Directors -3.5%
4/24 Form DEF 14A SUTRO BIOPHARMA, INC. For: Jun 05 -16.5%
10/7 Sutro Bio up 22% after mixed shelf filing [Seeking Alpha] -12.6%
3/10 Sutro Biopharma Inc (NASDAQ: STRO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -10.4%
2/27 Sutro Biopharma to Present at the Cowen and Company 40th Annual Health Care Conference -8.3%
5/14 Q1/2019 3/31/2019 EPS -0.620 ZacksConsensus N/A ActVsEst N/A - N/A -7.7%
8/14 Q2/2019 6/30/2019 EPS -0.600 ZacksConsensus N/A ActVsEst N/A - N/A -7.0%
9/30 Form 4 SUTRO BIOPHARMA, INC. For: Sep 26 Filed by: ALBINI EDWARD C -4.4%
3/12 Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck -3.9%
1/8 Sutro Biopharma Appoints James Panek to Board of Directors -3.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: